Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.78
ACUR's Cash-to-Debt is ranked lower than
69% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. ACUR: 0.78 )
Ranked among companies with meaningful Cash-to-Debt only.
ACUR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 1.27 Max: No Debt
Current: 0.78
Equity-to-Asset 0.19
ACUR's Equity-to-Asset is ranked lower than
98% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ACUR: 0.19 )
Ranked among companies with meaningful Equity-to-Asset only.
ACUR' s Equity-to-Asset Range Over the Past 10 Years
Min: -7.86  Med: 0.16 Max: 0.97
Current: 0.19
-7.86
0.97
Piotroski F-Score: 5
Altman Z-Score: -58.60
Beneish M-Score: -3.05
WACC vs ROIC
13.87%
-129.96%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -40.78
ACUR's Operating Margin % is ranked lower than
90% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. ACUR: -40.78 )
Ranked among companies with meaningful Operating Margin % only.
ACUR' s Operating Margin % Range Over the Past 10 Years
Min: -11455.28  Med: -146.89 Max: 51.47
Current: -40.78
-11455.28
51.47
Net Margin % -51.73
ACUR's Net Margin % is ranked lower than
91% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. ACUR: -51.73 )
Ranked among companies with meaningful Net Margin % only.
ACUR' s Net Margin % Range Over the Past 10 Years
Min: -11301.63  Med: -165.5 Max: 50.74
Current: -51.73
-11301.63
50.74
ROE % -204.54
ACUR's ROE % is ranked lower than
97% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. ACUR: -204.54 )
Ranked among companies with meaningful ROE % only.
ACUR' s ROE % Range Over the Past 10 Years
Min: -204.54  Med: -47.29 Max: 51.89
Current: -204.54
-204.54
51.89
ROA % -36.39
ACUR's ROA % is ranked lower than
93% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. ACUR: -36.39 )
Ranked among companies with meaningful ROA % only.
ACUR' s ROA % Range Over the Past 10 Years
Min: -59.15  Med: -36.27 Max: 33.14
Current: -36.39
-59.15
33.14
ROC (Joel Greenblatt) % -172.91
ACUR's ROC (Joel Greenblatt) % is ranked lower than
90% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. ACUR: -172.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACUR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1226.13  Med: -945.65 Max: 1628.06
Current: -172.91
-1226.13
1628.06
3-Year Revenue Growth Rate 207.00
ACUR's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. ACUR: 207.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ACUR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -31.5 Max: 207
Current: 207
0
207
3-Year EBITDA Growth Rate -28.90
ACUR's 3-Year EBITDA Growth Rate is ranked lower than
93% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. ACUR: -28.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACUR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -60.2  Med: -3.7 Max: 143.7
Current: -28.9
-60.2
143.7
3-Year EPS without NRI Growth Rate -24.70
ACUR's 3-Year EPS without NRI Growth Rate is ranked lower than
83% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. ACUR: -24.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACUR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -84.9  Med: -1.5 Max: 56.2
Current: -24.7
-84.9
56.2
GuruFocus has detected 1 Warning Sign with Acura Pharmaceuticals Inc $ACUR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACUR's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ACUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:RSPI, OTCPK:NRXCF, OTCPK:ULUR, OTCPK:LBLTF, OTCPK:ADMD, OTCPK:YBAO, NAS:DCTH, OTCPK:PUFXF, OTCPK:NUVPF, AMEX:IGC, OTCPK:BLONF, OTCPK:AQSZF, NAS:APRI, OTCPK:RLMD, NAS:MYOS, OTCPK:AOLS, OTCPK:CBICF, OTCPK:PVCT, OTCPK:CYIG, OTCPK:PARNF » details
Traded in other countries:HD4B.Germany,
Headquarter Location:USA
Acura Pharmaceuticals Inc is a pharmaceutical company. It is engaged in the research, development & manufacture of product to address medication abuse & misuse.

Acura Pharmaceuticals Inc is a specialty pharmaceutical company engaged in the research, development and commercialization of products intended to address medication abuse and misuse.The Company have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Its Aversion and Limitx Technologies are intended to address methods of abuse associated with opioid analgesics while the Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine.Its competitors include, Pain Therapeutics, Pfizer Inc., Purdue Pharma, Atlantic Pharmaceuticals, Egalet Corporation, KemPharm, Shionogi, Nektar Therapeutics, Signature Therapeutics, QRx Pharma, Tris Pharma, Pisgah Labs, Teva Pharmaceuticals, Sun Pharmaceuticals, Ensysce Biopharma, Inspirion Delivery Sciences and Collegium Pharmaceuticals.

Top Ranked Articles about Acura Pharmaceuticals Inc

Acura Pharmaceutical's LIMITX(TM) Technology Successfully Confirms Oral Abuse Deterrence Capabilities

Topline Results From Study AP-LTX-400 Cohort 2
PALATINE, IL--(Marketwired - June 08, 2016) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that topline results from cohort 2 of clinical study AP-LTX-400 (Study 400) confirmed that LTX-04P tablets, a hydromorphone hydrochloride immediate-release tablet using the Company's new LIMITX oral abuse deterrent technology, successfully retarded the release of the active opioid ingredient when four, six and eight intact tablets were ingested. The Company previously announced similar abuse deterrent findings from cohort 1 of Study 400 for a 3 tablet dose of LTX-04P but that additional formulation development will be required for LTX-04P to deliver a sufficient amount of the active ingredient to patients when one or two tablets are administered. The Company expects to resume clinical testing of a new formulation of LTX-04 in the fourth quarter of 2016 following completion of ongoing reformulation work and a discussion with the U.S. Food and Drug Administration (FDA) regarding the results of Study 400.The patented LIMITX technology works by neutralizing stomach acid as increasing numbers of tablets are swallowed and relying on stomach acid to play a role in the release of the active ingredient from micro-particles contained in the tablets. Cohort 2 of Study 400 studied 4, 6 and 8 tablet dosage subgroups of LTX-04P against the marketed comparator product, DILAUDID. Cohort 1 studied 1, 2 and 3 tablet dosage subgroups. Study 400 measured the rate and extent of absorption of the active drug ingredient into the blood stream with the maximum drug concentration, or Cmax, typically associated with an increase in drug abuse. Subjects in Study 400 had an average 22% reduction in relative Cmax when 3 or more tablets were ingested as shown in the table below. 
Study 400 - Mean Ratio of Cmax (ng/mL) by Dosing Group
Compared to the 1 Tablet Group for the Same Formulation

 
 Dosing in mg
 DILAUDID
 LTX-04P
 Change

2 Tablet Group
 2x
 1.9x
 2.2x
 15%

3 Tablet Group
 3x
 4.8x
 3.8x
 -22%

4 Tablet Group
 4x
 6.4x
 4.8x
 -25%

6 Tablet Group
 6x
 6.2x
 5.2x
 -15%

8 Tablet Group
 8x
 8.4x
 6.8x
 -18%

 Average 3-8
  
  
  
 -22%
All Subjects in cohort 2 had extent of drug absorption (measured by AUC) for LTX-04P comparable to DILAUDID when the same number of tablets were ingested. Likewise, the time to maximum plasma concentration, or Tmax, was comparable at all doses. All doses in Study 400 were generally well tolerated with no serious adverse event reported.Dr. Al Brzeczko, Acura's Vice President of Technical Affairs commented, "We are excited the dosing levels studied in cohort 2 of Study 400 confirmed the LIMITX technology concept of reducing Cmax as higher, more abused doses are ingested. Study 400 provided us with a wealth of data that we will mine to adjust our formulation to achieve better performance for the one and two tablet doses. We will also look to see if we can improve upon the abuse deterrent performance as well." "To see this level of abuse deterrence with our first test formulation is wonderful for this new technology," noted Bob Jones, President and CEO of Acura. "We look forward to completing our analysis of Study 400, finishing our reformulation and getting back in the clinic as soon as possible."The Company continues to advance its reformulation work on the LIMITX technology micro-particles to improve the drug delivery with one and two tablets and hopes to have a dialogue with the FDA regarding these results and the next clinical phase under its Fast Track development designation for LTX-04.About Study AP-LTX-400StudyAP-LTX-400 (Study 400) is a two cohort, open label, crossover design pharmacokinetic study in healthy adult subjects. Cohort 1 enrolled 30 subjects who were randomized into three subgroups of 10 taking either 1, 2 or 3 tablets. Each subgroup subject orally swallowed the planned number of tablets in a randomized manner taking single doses of two different test formulations of LTX-04 (designated as LTX-04P and LTX-04S) and the marketed drug DILAUDID as a comparator. All tablets contained 2mg of hydromorphone hydrochloride. The 1, 2 and 3 tablets subgroups in Cohort 1 completed 8, 10 and 8 subjects, respectively. Cohort 2 enrolled 30 subjects who were randomized into three subgroups of 10 taking either 4, 6 or 8 tablets. Each subgroup subject orally swallowed the planned number of tablets in a randomized manner taking single doses of LTX-04P and the marketed drug DILAUDID as a comparator. The 4, 6 and 8 tablets subgroups in Cohort 2 completed 8, 9 and 8 subjects, respectively.All tablets contained 2mg of hydromorphone hydrochloride. All subjects received doses of naltrexone and there was a one week washout between doses. Blood samples were taken at pre-designated time-points after dosing and were subsequently analyzed for the concentration of hydromorphone contained in the sample. All subjects in Cohort 1 had continuous pH (a measure of acid concentration) monitoring of their stomach acid. The objective of Cohort 1 was to determine if adequate active drug entered the blood stream when one or two LIMITX tablets were swallowed and to begin assessing the ability of the LIMITX technology to start retarding the release of active ingredients when three tablets are ingested. The objective of Cohort 2 was to further explore the extent the release of the hydromorphone active ingredient from LTX-04P tablets is retarded as the dose level increases to abusive levels. A safety assessment of LIMITX Hydromorphone will be made from both study cohorts. LTX-04 is being developed in part with a grant from the National Institute on Drug Abuse (NIDA). NIDA is not responsible for the results of any of the research. The LTX-04 development program is also designated as Fast Track by the FDA for its potential to address an unmet medical need.To further discuss these results Acura's management will host a live conference call and webcast at 8:30 am ET on Thursday, June 9, 2016. The presentation will be webcast live and may be accessed by visiting the Company's website, Acurapharm.com and selecting the "News and Events" option under the "Investors" tab. For those wishing to listen only you may dial 1-888-576-4398 with passcode 1705487. A replay of the webcast will be available for 60 days on the Acura website.About Acura PharmaceuticalsAcura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITX™, AVERSION® and IMPEDE® Technologies. LIMITX contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages if the product is snorted. IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.OXAYDO® (oxycodone HCl immediate-release tablets) which incorporates the AVERSION Technology, is FDA approved and marketed in the U.S. by our partner Egalet Corporation. Acura markets NEXAFED® and NEXAFED® Sinus, which are pseudoephedrine containing products that utilize the IMPEDE Technology.Forward-Looking StatementsCertain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements may include, but are not limited to:our ability to fund or obtain funding for our continuing operations, including the development of our products utilizing our LIMITX and Impede® technologies;the expected results of clinical studies relating to LTX-04P, the date by which such study results will be available and whether LTX-04P will ultimately receive FDA approval; whether LIMITX will retard the release of opioid active ingredients as dose levels increase;whether we will be able to reformulate LTX-04P to provide an efficacious level of drug when one or two tablets are taken;whether we will be able to reformulate LTX-04P to improve its abuse deterrent performance;whether the extent to which products formulated with the LIMITX technology deter abuse will be determined sufficient by the FDA to support approval or labelling describing abuse deterrent features;whether our LIMITX technology can be expanded into extended-release formulations; our and our licensee's ability to successfully launch and commercialize our products and technologies, including Oxaydo® Tablets and our Nexafed® products;our and our licensee's ability to obtain necessary regulatory approvals and commercialize products utilizing our technologies;the market acceptance of, timing of commercial launch and competitive environment for any of our products;expectations regarding potential market share for our products;our ability to develop and enter into additional license agreements for our product candidates using our technologies;the ability to avoid infringement of patents, trademarks and other proprietary rights of third parties;the ability of our patents to protect our products from generic competition and our ability to protect and enforce our patent rights in any paragraph IV patent infringement litigation;the ability to fulfill the FDA requirements for approving our product candidates for commercial manufacturing and distribution in the United States, including, without limitation, the adequacy of the results of the laboratory and clinical studies completed to date, the results of laboratory and clinical studies we may complete in the future to support FDA approval of our product candidates and the sufficiency of our development process to meet over-the-counter ("OTC") Monograph standards, as applicable;the adequacy of the development program for our product candidates, including whether additional clinical studies will be required to support FDA approval of our product candidates;changes in regulatory requirements;adverse safety findings relating to our commercialized products or product candidates in development;whether the FDA will agree with our analysis of our clinical and laboratory studies; whether further studies of our product candidates will be required to support FDA approval;whether or when we are able to obtain FDA approval of labeling for our product candidates for the proposed indications and whether we will be able to promote the features of our abuse discouraging technologies; andwhether Oxaydo or our Aversion and LIMITX product candidates will ultimately deter abuse in commercial settings and whether our Nexafed products and Impede technology product candidates will disrupt the processing of pseudoephedrine into methamphetamine.In some cases, you can identify forward-looking statements by terms such as "may," "will", "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "indicates", "projects," predicts," "potential" and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in our filings with the Securities and Exchange Commission.DILAUDID is a trademark of Purdue Pharma L.P.
Contact:
for Acura Investor Relations
Email contact

847-705-7709

Renmark Financial Communications Inc.
Robert Thaemlitz
Email contact

(416) 644-2020 or (514) 939-3989
www.renmarkfinancial.com



Read more...

Ratios

vs
industry
vs
history
PB Ratio 3.47
ACUR's PB Ratio is ranked lower than
99.99% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. ACUR: 3.47 )
Ranked among companies with meaningful PB Ratio only.
ACUR' s PB Ratio Range Over the Past 10 Years
Min: 1.61  Med: 5.03 Max: 18.41
Current: 3.47
1.61
18.41
PS Ratio 0.86
ACUR's PS Ratio is ranked higher than
64% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. ACUR: 0.86 )
Ranked among companies with meaningful PS Ratio only.
ACUR' s PS Ratio Range Over the Past 10 Years
Min: 0.79  Med: 9.21 Max: 1011.11
Current: 0.86
0.79
1011.11
Current Ratio 1.53
ACUR's Current Ratio is ranked lower than
81% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. ACUR: 1.53 )
Ranked among companies with meaningful Current Ratio only.
ACUR' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.23 Max: 68.17
Current: 1.53
0.02
68.17
Quick Ratio 1.53
ACUR's Quick Ratio is ranked lower than
72% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. ACUR: 1.53 )
Ranked among companies with meaningful Quick Ratio only.
ACUR' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.79 Max: 68.17
Current: 1.53
0.01
68.17
Days Inventory 213.18
ACUR's Days Inventory is ranked lower than
83% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. ACUR: 213.18 )
Ranked among companies with meaningful Days Inventory only.
ACUR' s Days Inventory Range Over the Past 10 Years
Min: 161.36  Med: 341.46 Max: 752.41
Current: 213.18
161.36
752.41
Days Sales Outstanding 0.31
ACUR's Days Sales Outstanding is ranked higher than
92% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. ACUR: 0.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACUR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.31  Med: 28.99 Max: 575.69
Current: 0.31
0.31
575.69
Days Payable 159.93
ACUR's Days Payable is ranked higher than
97% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. ACUR: 159.93 )
Ranked among companies with meaningful Days Payable only.
ACUR' s Days Payable Range Over the Past 10 Years
Min: 61.2  Med: 205.62 Max: 877.28
Current: 159.93
61.2
877.28

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.00
ACUR's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. ACUR: -7.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACUR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -166.7  Med: -8.4 Max: 0
Current: -7
-166.7
0

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 16.67
ACUR's Price-to-Tangible-Book is ranked lower than
99.99% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. ACUR: 16.67 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ACUR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.4  Med: 5.36 Max: 205.56
Current: 16.67
1.4
205.56
Price-to-Median-PS-Value 0.09
ACUR's Price-to-Median-PS-Value is ranked higher than
98% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. ACUR: 0.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACUR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.26 Max: 118.75
Current: 0.09
0.05
118.75
Earnings Yield (Greenblatt) % -39.54
ACUR's Earnings Yield (Greenblatt) % is ranked lower than
100% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. ACUR: -39.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACUR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -39.54  Med: 8.7 Max: 48.2
Current: -39.54
-39.54
48.2

More Statistics

Revenue (TTM) (Mil) $6.96
EPS (TTM) $ -0.31
Beta1.98
Short Percentage of Float1.20%
52-Week Range $0.40 - 3.28
Shares Outstanding (Mil)11.88

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1 32 87
EPS ($) -0.44 0.37 0.84
EPS without NRI ($) -0.44 0.37 0.84
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ACUR

Headlines

Articles On GuruFocus.com
Acura Pharmaceutical's LIMITX(TM) Technology Successfully Confirms Oral Abuse Deterrence Capabilitie Jun 08 2016 
Acura Pharmaceuticals Announces First Quarter 2016 Financial Results May 02 2016 
Indiana Governor's Bill Signing Ceremony Recognizes the Role of Meth-Resistant Technology in Stemmin Apr 28 2016 
Acura Pharmaceuticals Receives Second U.S. Patent for Novel Limitx(TM) Abuse Deterrent Technology Apr 26 2016 
Acura Pharmaceuticals to Host First Quarter 2016 Financial Results Conference Call on May 3, 2016 Apr 21 2016 
Acura Pharmaceutical's Limitx(TM) Technology Successfully Demonstrates Oral Abuse Deterrence Apr 13 2016 
Acura Pharmaceuticals Announces FDA Fast Track Designation for the Development of LTX-04 Apr 12 2016 
Acura Pharmaceuticals' Universal Shelf Registration Statement Declared Effective Mar 30 2016 
What to Watch for: November 3-7 Nov 04 2014 
Acura Pharmaceuticals Hydrocodone Bitartrate With Acetaminophen Tablets Meet Clinical Endpoints Oct 15 2014 

More From Other Websites
Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 May 24 2017
Acura Pharmaceutical Initiates Second Clinical Study on LTX-04 May 18 2017
Acura Pharmaceuticals Announces First Quarter 2017 Financial Results May 12 2017
ETFs with exposure to Acura Pharmaceuticals, Inc. : April 5, 2017 Apr 05 2017
Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q4, 2016 By the Numbers : April 4, 2017 Apr 04 2017
Edited Transcript of ACUR earnings conference call or presentation 3-Apr-17 12:30pm GMT Apr 03 2017
Acura Pharmaceuticals Announces Fourth Quarter 2016 and Full Year 2016 Financial Results Mar 31 2017
Acura Pharmaceuticals and MainPointe Pharmaceuticals Announce Deal for Nexafed® Products Mar 17 2017
Implied Volatility Surging for Acura (ACUR) Stock Options Jan 10 2017
ETFs with exposure to Acura Pharmaceuticals, Inc. : December 23, 2016 Dec 23 2016
Acura Pharmaceutical Provides Development Update on its LIMITx(TM) Technology Dec 14 2016
Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016 Nov 18 2016
Acura Pharmaceuticals Announces Third Quarter 2016 Financial Results Nov 14 2016
Acura Pharmaceuticals to Host Third Quarter 2016 Financial Results Conference Call on November 15,... Nov 09 2016
ETF’s with exposure to Acura Pharmaceuticals, Inc. : October 18, 2016 Oct 18 2016
KemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion(R) Abuse-Deterrent... Oct 18 2016
Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 Aug 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)